Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star Seyedkazemi, chief development officer of Adverum Biotechnologies, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on Wednesday, November 29, 2023 at 3:50 p.m. ET in Miami, Florida.
Related news for (ADVM)
- MoBot’s Stock Market Highlights – 09/23/25 11:00 AM
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
- Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
- Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
- adverum biotechnologies appoints jason l. mitchell as chief commercial officer as it prepares to initiate pivotal program